이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Inari Medical 배당금

배당금 기준 확인 0/6

Inari Medical 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	1.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$0.41
3년 후 배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

At US$43.23, Is It Time To Put Inari Medical, Inc. (NASDAQ:NARI) On Your Watch List?

Jun 18

Market Participants Recognise Inari Medical, Inc.'s (NASDAQ:NARI) Revenues Pushing Shares 26% Higher

May 23

Is Inari Medical, Inc. (NASDAQ:NARI) Trading At A 29% Discount?

May 02

Inari Medical: Buy On Growing TAM

Mar 27

Why We're Not Concerned Yet About Inari Medical, Inc.'s (NASDAQ:NARI) 25% Share Price Plunge

Mar 08

Inari Medical, Inc. (NASDAQ:NARI) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jul 25

We Think Inari Medical (NASDAQ:NARI) Can Afford To Drive Business Growth

Jun 18

Inari Medical, Inc.'s (NASDAQ:NARI) Price In Tune With Revenues

Apr 17

Is Inari Medical, Inc. (NASDAQ:NARI) Potentially Undervalued?

Dec 07

Study assessing Inari Medical's blood clot removal system shows low rate of adverse events

Sep 19

Inari Medical: Growth Set To Reaccelerate In The Back Half Of The Year

Sep 07

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 NARI 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: NARI 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Inari Medical 시장 대비 배당 수익률

NARI 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (NARI)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Medical Equipment)	1.8%
3년 후 애널리스트 예측 (NARI)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 NARI 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 NARI 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 NARI 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: NARI 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Inari Medical 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Inari Medical, Inc

At US$43.23, Is It Time To Put Inari Medical, Inc. (NASDAQ:NARI) On Your Watch List?

Chief Financial Officer notifies of intention to sell stock

Director notifies of intention to sell stock

Now 22% overvalued

Market Participants Recognise Inari Medical, Inc.'s (NASDAQ:NARI) Revenues Pushing Shares 26% Higher

Chief Financial Officer exercised options and sold US$273k worth of stock

Grant & Eisenhofer Files Class Action Lawsuit Against Inari Medical, Inc., William Hoffman, Andrew Hykes, and Mitch C. Hill on Behalf of Institutional Investor

Consensus EPS estimates fall by 73%, revenue upgraded

Inari Medical, Inc. Provides Earnings Guidance for the Full Year 2024

Price target decreased by 7.4% to US$66.00

Is Inari Medical, Inc. (NASDAQ:NARI) Trading At A 29% Discount?

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Inari Medical, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Chief Financial Officer exercised options and sold US$243k worth of stock

Inari Medical, Inc. Appoints Tim Benner as Senior Vice President of U.S. Sales

Inari Medical: Buy On Growing TAM

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc., Annual General Meeting, Apr 24, 2024

Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry

Why We're Not Concerned Yet About Inari Medical, Inc.'s (NASDAQ:NARI) 25% Share Price Plunge

Consensus EPS estimates fall by 325%

Price target decreased by 7.5% to US$76.50

Full year 2023 earnings: EPS misses analyst expectations

Inari Medical, Inc. Provides Revenue Guidance for the Full Year 2024

Inari Medical, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Consensus EPS estimates fall by 16%

Inari Medical, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Full Year of 2023 and 2024

Chief Financial Officer exercised options and sold US$405k worth of stock

Is Now The Time To Look At Buying Inari Medical, Inc. (NASDAQ:NARI)?

Inari Medical, Inc. Announces the First Patient Enrollment in the PEERLESS II Study

Inari Medical, Inc. Announces the First Patient Enrollment in the PEERLESS II Study

CEO, President & Director recently sold US$2.2m worth of stock

Inari Medical, Inc. (NasdaqGS:NARI) completed the acquisition of LimFlow SA.

CEO, President & Director notifies of intention to sell stock

Independent Chair of the Board recently bought US$3.0m worth of stock

Inari Medical, Inc. (NasdaqGS:NARI) agreed to acquire LimFlow SA for $415 million.

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Inari Medical, Inc. (NASDAQ:NARI)

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Inari Medical (NASDAQ:NARI) Is In A Strong Position To Grow Its Business

Chief Financial Officer exercised options and sold US$438k worth of stock

CEO, President & Director recently sold US$2.4m worth of stock

CEO, President & Director notifies of intention to sell stock

Is Inari Medical, Inc. (NASDAQ:NARI) Potentially Undervalued?

Inari Medical, Inc. Raises Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Inari Medical, Inc. (NASDAQ:NARI) Shares Could Be 23% Above Their Intrinsic Value Estimate

Chief Financial Officer exercised options and sold US$363k worth of stock

Inari Medical, Inc. to Report Q2, 2023 Results on Aug 02, 2023

We Think Inari Medical (NASDAQ:NARI) Can Afford To Drive Business Growth

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc. Announces Commercial Launch of Revcore and Triever16 Curve, Two New Purpose-Built Products for Addressing Venous Stent Thrombosis and Venous Thromboembolism

Inari Medical, Inc Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism Patients

Director recently sold US$5.7m worth of stock

Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 58%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Inari Medical, Inc. Revises Revenue Guidance for the Full Year 2023

Inari Medical, Inc.'s (NASDAQ:NARI) Price In Tune With Revenues

Chief Financial Officer exercised options and sold US$415k worth of stock

Independent Director exercised options and sold US$1.6m worth of stock

Chief Medical Officer exercised options and sold US$563k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 78%, revenue upgraded

Chief Financial Officer notifies of intention to sell stock

Inari Medical, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Chief Medical Officer notifies of intention to sell stock

Chief Financial Officer exercised options and sold US$425k worth of stock

Inari Medical, Inc. Announces First Patient Enrolled in the DEFIANCE Trial

Inari Medical, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2022 and for the Full Year 2023

CEO, President & Director exercised options and sold US$98k worth of stock

Chief Medical Officer exercised options and sold US$628k worth of stock